ClinicalTrials.gg
CompletedNCT06858904TRACEUpdated Sep 5, 2025

Rehydration With a Trace Mineral Supplement

An interventional study of Placebo and ConcenTrace in Dehydration (Physiology), sponsored by Arizona State University. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-05.

Sponsored by Arizona State University · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

It is well established that post-exercise rehydration with electrolyte solutions is more effective than plain water. However, most commercially available drinks are high in electrolytes but lack some essential trace minerals. This study aims to examine the impact of a higher-electrolyte sports drink compared with a low-electrolyte, trace-mineral-rich solution and water on the time course and extent of rehydration after exercise-induced dehydration.

Read the detailed description

Protocol Before the start of the study eligible participants will visit our lab to conduct a screening of medical history, weight, height, and a onetime assessment of body composition via BIA and Training history. This visit will take place at least one day before the actual start of the study and typically lasts no longer than 30 minutes. During this visit participants will be given two questionnaires, one regarding the physical activity readiness of the participant, and another one regarding their health history. If a participant does not meet the physical criteria and does not pass both questionnaires, they will be given a $25 digital Tango gift card for their brief visit to our lab. Participants who do pass will be given a scheduled date and time to visit the lab again for their first official trial.

At the start of the study subjects will visit the lab after at least 10h of fast and they will consume a light breakfast. An intravenous catheter will be place in an antecubital vein and a blood sample will be taken after 20 min for baseline. A baseline skin hydration reading will also be taken at this time. Subjects will void their bladders and a body weight will be taken.

Dehydration:

Consistent with the study by Shirreffs et al (2007) and based on our previous work, dehydration will be accomplished on the morning of testing via mild exercise and heat exposure to elicit a body weight loss of -2%. The subjects will perform four bouts of 25-minutes low-intensity exercise and 5 min rest (alternating cycling \& walking) or till they reach -2% of body weight dehydration.

Rehydration:

Upon losing 2% body weight, participants will be instructe to rinse off their face to get rid of excess sweat. This is followed by a 20 minutes rest period in a thermo-comfortable environment, a dehydrated baseline blood sample will be taken, along with a dehydrated skin hydration reading and subject will start the rehydration protocol.

The volunteers will consume one of the three drinks below in a cross over balance mode. During the first hour four equal doses will be consumed in15-minutes intervals at a total volume of 150% of their body weight loss.

Trials/Drinks (block randomization will be used to assign individual participants to each specific trial/drink using their ID number):

  • Water
  • ConcenTrace®
  • ZEROLyte™ Note: The beverage volumes will be standardized at 150% of body weight loss during exercise-induced dehydration to ensure consistency across trials.

See the study design expressed as a figure below:

Measurements:

All measurements will be performed at one of the test rooms at our lab facility that boarders the room where participants can relax and wait out the end of the study day. When certain measurements need to be performed they simply move from one room to the next. Duration of taking blood and urine samples will take not more than 30-90 seconds each and perceptual data will take 30-60 seconds to be reported. To allow to perform all measurements, participants will remain supervised by a team member in the lab for up to 7 hours per trial. Therefore, there will be a separate space available that allows for self-study or watching TV that includes a chair and table to work on and a couch to relax.

Blood samples (7 per trial):

Blood samples will be taken via a venous catheter attached to an extension tube and a stopcock. After each blood sample sterile saline solution will be infused in the extention tube to avoid clotting. The iv catheter will be placed by one of the Clinical Research Center phlebotomists. A total of seven 10 milliliters blood samples will be collected on the euhydrated baseline, dehydrated baseline and at 30, 60, 120, 180, and 240 minutes of the rehydration period.

All samples will be analyzed for glucose, osmolality, total plasma protein, hematocrit, hemoglobin (for plasma volume changes), sodium, potassium, and chloride.

Urine samples (6 per trial):

Urine samples will be provided from the subjects in a urine cup. The cup will be placed in the pass-through window where a lab technician will receive it and process it.

Urine samples will be collected using \~900 milliliters cups at euhydrated baseline, dehydrated baseline and cumulative totals will be collected at 60, 120, 180, and 240 minutes of the rehydration period. All samples will be analyzed for urine osmolality, specific gravity, volume, sodium, and potassium.

Sweat samples (1 per trial):

Sweat samples will be collected with sweat patches. The sweat patches are like a band-aid that it will be placed on the forearm and stay there for approximately 30 min to absorb sweat. After 30 minutes the patch will be removed and the sweat sample will be extracted by centrifugation in the lab.

Sweat samples will be collected during the first 30 min of exercise to assess sodium and potassium content.

Skin Hydration (6 per trial):

Skin hydration will be measured with a pen-like instrument that applies a very light pressure on the skin. This does not cause any pain or skin irritation.

Skin hydration will be measured on the face (inner zygomatic bone), arm (bicep brachii) at euhydrated baseline, 30 minutes after the end of dehydration, and at 60, 120, 180, and 240 minutes of rehydration.

Gastrointestinal Symptoms (6 per trial):

Gastrointestinal symptoms will be assessed at 1, 2, 3 and 4 hours of rehydration via Gastrointestinal Symptom Rating Scale (GSRS).

Perceptual Data (6 per trial, maximal 9 minutes):

Thirst, stomach fullness, and taste, assessed via a visual analog scale.

02

Conditions studied

  • Dehydration (Physiology)

Browse trials for

Keywords

  • rehydration
  • sports drinks
  • fluid balance
  • water retention
03

In context

Dehydration

201 studies on the registry are indexed under Dehydration; 28 are open to participants now.

This study's enrollment of 15 is below the median of 43 across 145 interventional studies indexed under Dehydration.

Browse Dehydration studies →

Lead sponsor

Arizona State University is the lead sponsor of 238 studies on the registry; 42 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Recreationally physically active: Training > 2x per week and ≤ 6hours per week
  • of 18.5-29.9
  • Stable weight for the last 2 months (\<5 pounds. fluctuation)

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant, breast feeding, or planning to become pregnant during the trial
  • night shifting work
  • thyroid medication
  • bariatric surgery
  • cardiovascular disease
  • renal disease
  • hepatic disease
  • Participating in another study at the same time
  • Bodyweight \<110 pounds
  • Currently Smoker
  • Major surgery, including abdominal, in the past 3 months or individuals who have planned surgery during the trial.
  • Alcohol or drug abuse within the last 12 months
  • High alcohol intake (average of > 2 standard drinks per day or > 10 standard drinks per week)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    ConcenTrace

    Beverage with ConcenTrace minerals

    Dietary Supplement: ConcenTrace

  • Experimental
    ZeroLyte

    Beverage with high level of trace elements but no sugar

    Dietary Supplement: ZeroLyte

  • Placebo comparator
    Placebo

    Water with non caloric, non-sodium containing sweetner

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementPlacebo

    Non- calorically sweetened Water

  • Dietary supplementConcenTrace

    1.25 milliliter of concentrace per liter

  • Dietary supplementZeroLyte

    Beverage with 1 pack of ZeroLyte per 500 milliliter of water

06

What researchers measure

Primary outcomes

  1. Net Fluid Balance

    Body water Retention after exercise-induced dehydration

    Time frame: at 60 minutes, 120 minutes, 180 minutes and 240 minutes of rehydration

  2. Urine volume

    Urine volume during the rehydration period

    Time frame: 1, 2, 3, and 4 hour of the rehydration period

  3. Free water clearance

    Free water clearance during the rehydration period

    Time frame: 1, 2, 3, and 4 hours of the rehydration period

  4. Osmotic Clearance

    Osmotic renal clearance during the rehydration period

    Time frame: 1, 2, 3, and 4 hours of the rehydration period

  5. Skin Hydration

    Skin hydration at the face assessed with a moisture meter.

    Time frame: 1, 2, 3, and 4 hours of the rehydration period

Secondary outcomes

  1. Plasma Volume

    Changes in Plasma Volume during rehydration based on hematocrit and hemoglobin

    Time frame: 1, 2, 3, and 4 hours of the rehydration period

  2. Stomach fullness

    Stomach fullness assessed during dehydration

    Time frame: 1, 2, 3, and 4 hours of the rehydration period

  3. Gastrointestinal symptoms

    Gastrointestinal symptoms assessed with the structured assessment of gastrointestinal symptoms scale

    Time frame: At the end of the 4 hours rehydration period

  4. Plasma Osmolality

    Plasma osmolality during rehydration

    Time frame: 1, 2, 3, and 4 hours of the rehydration period

07

Study locations

1 site
  • Hydration Science Lab
    Phoenix, Arizona 85004, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2025 to primary completion in Aug 2025, 5 months.

Of 65 non-industry interventional studies with no phase under Dehydration, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 18. This study's 5 months is below that.

Counting every sponsor, half of 73 studies reached it within 9 months; a quarter within 5 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2025
First posted
Mar 5, 2025
StartActual
Mar 26, 2025
Primary completionActual
Aug 29, 2025
CompletionActual
Aug 29, 2025
Last update
Sep 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06858904
Responsible party
Stavros Kavouras (Professor and Assistant Dean, Arizona State University) — Principal investigator
First posted
Mar 5, 2025
Start date
Mar 26, 2025
Primary completion
Aug 29, 2025
Completion
Aug 29, 2025
Last update
Sep 5, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion